Xamoterol

This classification denotes a beta-adrenergic agonist with the molecular formula C16H25N3O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7HE0JQL703, chemically known as 4-morpholinecarboxamide, n-(2-((2-hydroxy-3-(4-hydroxyphenoxy)propyl)amino)ethyl)-, (+-)- but generally known as xamoterol, which bears US NIH Compound Identifier 155774. European Medicines Agency schedules Xamoterol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00092MIG. The term XAMOTEROL is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 37, No. 6, 1983, List 23). World Health Organization schedules xamoterol in its Anatomical Therapeutic Chemical (ATC) Classification. XAMOTEROL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule xamoterol under HS 29349990 and SITC 51579. As of Q4 2014, XAMOTEROL remains the US FDA Preferred Term for this commodity. Xamoterol bears US NLM identifiers UMLS ID C0078595 and NCI Concept Code C81344. SMILES: O1CCN(CC1)C(=O)NCCNCC(O)COC1CCC(O)CC1.